Abiraterone Acetate Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Deleterious HRR Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK2 Gene Mutation; FANCA Gene Mutation; PALB2 Gene Mutation; RAD51B Gene Mutation; RAD54L Gene Mutation Interventions: Drug: Androgen deprivation therapy (ADT); Drug: Niraparib/Abiraterone Acetate; Drug: Abiraterone acetate; Drug: Prednisone; Drug: Docetaxel Sponsors: Qian Qin; UT Southwestern Comprehensive Cancer Center; Janssen, LP Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) MRI as a Response Monitoring Tool to Neoadjuvant Abiraterone
Conditions: High Risk Prostate Carcinoma; Prostate Cancer Interventions: Drug: Abiraterone acetate; Drug: Prednisone; Drug: Hyperpolarized [1-13C] pyruvate (HP 13C); Procedure: Magnetic Resonance Imaging (MRI); Procedure: Non-investigational radical prostatectomy (RP); Procedure: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT) Sponsors: Ivan de Kouchkovsky, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
Conditions: Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma Interventions: Drug: Abiraterone Acetate; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Gonadotropin-releasing Hormone Analog; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
Conditions: Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer Interventions: Drug: 177Lu-PSMA-617; Drug: Niraparib abiraterone acetate; Drug: Prednisone Sponsors: Rohan Garje; Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
Conditions: Prostate Cancer Metastatic Interventions: Radiation: Stereotactic Ablative Body Radiotherapy (SABR); Other: 177Lu-PSMA-617; Drug: Niraparib and Abiraterone Acetate Dual Action Tablet DAT; Drug: Abiraterone Acetate; Drug: Apalutamide; Drug: Androgen Deprivation Therapy (ADT); Drug: Androgen Receptor Signalling Inhibitor (ARSI); Radiation: Local Radiotherapy; Drug: Prednisolone; Drug: Docetaxel Sponsors: University College, London; Cancer Research UK; Novartis; Janssen Pharmaceutica NV Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials

High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Conditions: Prostate Cancer; Oligometastatic Disease Interventions: Drug: niraparib/abiraterone acetate; Radiation: Stereotactic ablative radiation therapy (SABR); Drug: Androgen deprivation therapy (ADT) Sponsors: University of Maryland, Baltimore; Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
Conditions: Prostate Cancer; Metastatic Cancer; Hormone Sensitive Prostate Cancer; Castration-resistant Prostate Cancer Interventions: Drug: Abiraterone Acetate Sponsors: National University Hospital, Singapore; National University of Singapore Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials

A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms Interventions: Drug: MK-5684; Drug: Dexamethasone; Drug: Fludrocortisone acetate; Drug: Hydrocortisone; Drug: Abiraterone acetate; Drug: Prednisone acetate; Drug: Enzalutamide Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials

Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003)
Conditions: Prostate Cancer Metastatic Interventions: Drug: MK-5684; Drug: Abiraterone acetate; Drug: Enzalutamide; Drug: Hydrocortisone; Drug: Fludrocortisone acetate; Drug: Prednisone; Drug: Dexamethasone Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials

AZD5305 vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Conditions: Metastatic Castration-Sensitive Prostate Cancer Interventions: Drug: AZD5305; Drug: Placebo; Drug: Abiraterone Acetate; Drug: Darolutamide; Drug: Enzalutamide Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Conditions: High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) Interventions: Drug: dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets; Drug: placebo; abiraterone acetate tablets; prednisone tablets Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects
Condition: Prostate Cancer Interventions: Drug: SOL-804-F; Drug: Zytiga Sponsors: Bukwang Pharmaceutical; Dyna Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials